Related Experiment Video

Updated: Dec 13, 2025

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells
05:27

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

2.1K

Latest Advances of Long Non-Coding RNA SNHG5 in Human Cancers

Wei Han1, Jia Shi1, Jiachao Cao1

  • 1Department of Neurosurgery, Third Affiliated Hospital of Soochow University, Changzhou, People's Republic of China.

Oncotargets and Therapy
|August 6, 2020
PubMed

Insights

Small nucleolar RNA host gene 5 (SNHG5), a long non-coding RNA, is frequently dysregulated in human cancers. This review highlights SNHG5's roles in tumor progression and potential as a clinical intervention target.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) play crucial roles in gene regulation, including in cancer development.
  • Aberrant expression of lncRNA small nucleolar RNA host gene 5 (SNHG5) is increasingly recognized in various solid tumors.

Purpose of the Study:

  • To review the latest research on the function of SNHG5 in human cancers.
  • To explore the potential of SNHG5 as a target for clinical interventions.

Main Methods:

  • Literature review of studies investigating SNHG5 in cancer.
  • Analysis of SNHG5's molecular mechanisms, including targeting miRNAs and signaling pathways.

Main Results:

  • SNHG5 expression correlates with tumor stage, metastasis, and patient prognosis.
  • SNHG5 influences key cancer cell activities such as proliferation, migration, invasion, cell cycle, apoptosis, and autophagy.

Conclusions:

  • SNHG5 is a significant oncogenic lncRNA with diverse roles in cancer progression.
  • Targeting SNHG5 presents a promising avenue for novel cancer therapies.
Keywords:
SNHG5biomarkerhuman cancerslncRNAtherapeutic target

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

940
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.7K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.9K
Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
97.0K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.7K